🔗 Share this article

While the United States undertakes historic changes to its immunization schedules, a particular individual has surfaced in a surprising turn: Dr. Tracy Beth Høeg, a US-based sports medicine doctor and public health researcher who initially gained attention by expressing skepticism about COVID-19 vaccines throughout the global health crisis and has zeroed in on possible fatalities following Covid immunization in her recent tenure at the Food and Drug Administration.

Proposed Shifts to Childhood Immunization Program

Health officials planned to unveil sweeping revisions to the childhood immunization program earlier this month, synchronizing the US with Denmark’s national calendar, it is understood – a substantial departure that would put the US out of alignment with a large portion of the world with no evidence for public health gain. This reveal has been delayed until the coming year.

Rather than the director of the vaccine center, Tracy Beth Høeg is set to address the audience at the meeting. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to run the center this year.

A Shift at the FDA

Høeg's temporary position could signify a strengthened alliance between the drug and biologics divisions as Dr. Høeg and Prasad strengthen their influence at the FDA – and it suggests a renewed priority upon rolling back already-approved vaccines at the FDA.

Høeg has frequently advocated for discontinuing specific childhood immunization guidelines in the US to become more like Denmark, a nation with universal health coverage and a citizenry about the size of Wisconsin’s.

In her initial comments, she has persisted in emphasizing on vaccination policy – traditionally the domain of Dr. Prasad, chief of the FDA’s CBER – rather than pharmaceutical oversight.

Concerns Over Background

Høeg has little discernible background in drug development, oversight or leadership, which has been standard for former leaders of the biologics center. She has worked at the FDA as a top consultant to the commissioner and CBER since earlier this year.

“She appears not to have the requisite experience” for leading the pharmaceutical oversight division, stated Dr. Jonathan Howard. “She has not conducted a scientific study. She is not versed in leading a major agency. She is not an expert in drug approvals.”

Previous directors of the center would “grasp regulatory frameworks and the underlying principles of pharmaceutical innovation”, said Janet Woodcock. “Frankly, she doesn’t have the type of experience that prior appointees who ran the center have had.”

This division has an enormous workload at the agency, the former commissioner pointed out.

“Everybody just zeroes in on the innovative therapies, but the generic drug division authorizes a multitude of generic drugs. There is also a biosimilars program, non-prescription drug unit and more, and all of those must be managed,” Woodcock explained. “The thing you overlook, that is precisely what that I always told people is going to cause problems.”

Additionally, a major management component to the position, which manages over 5,000 staff members. “It is a massive administrative position, if you do it right,” she added.

Response and Disputed Initiatives

Regarding concerns about Dr. Høeg's credentials and whether this appointment signifies increased cooperation among regulatory chiefs on immunizations, a spokesperson stated that the “questions stem from incorrect presumptions”.

“Her experience is consistent with the duties of her role,” the official stated, noting the time Høeg spent guiding the agency head on “drug safety and approval science, including computational safety modeling and immunization monitoring”.

As acting director, Dr. Høeg inherits the agency head's recently launched priority voucher program, a contentious expedited drug-approval program that allegedly concerned her former heads. “How are these therapies being picked for this expedited pathway? Who makes the decisions?” Dr. Howard said. “There is a lot of confidentiality happening at the FDA right now.”

In general, he said, “the Food and Drug Administration appears to be shifting towards more relaxed rules of pharmaceuticals, with the exception of shots.”

Documented History on Immunizations

Concerning vaccines, Dr. Høeg has a clearer, if problematic, past, Howard have noted. She published a research paper using unverified public submissions to estimate the frequency of myocarditis following Covid immunization. She consulted for the state of Florida surgeon general Joseph Ladapo, who allegedly have altered data to imply COVID-19 vaccinations are riskier than they are.

Part of her “policy goals” for the current government encompassed revising guidelines for novel immunizations and ending “unnecessary” vaccines, she stated post-election on a audio program. At the agency, Høeg has allegedly suggested barring teenage boys from obtaining COVID-19 vaccines.

“She is an complete true believer who begins with her conclusions and tailors the evidence to retrofit the data in a highly disingenuous, untruthful way,” Howard stated.

Gaining Influence and a “Revenge Tour”

Høeg became part of other contrarians, {like|